Author name: Leonardo Arias

Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase 3 win last week for their cancer vaccine plus Keytruda in melanoma.

For the second time in two years, Medtronic has pulled capsules from the market over a fault that could obstruct patients’ airways.

With Amulet 360, Abbott aims to capture share from Boston Scientific in the market for devices that seal the heart’s left atrial appendage to reduce stroke risk.

AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined with the standard of care for ATTR-CM, analysts say.

The attack has affected the company’s ability to manufacture products and to process and ship customers’ orders, and there is still no timeline for restoration.

More than 65% of physicians use AI daily or weekly for clinical or administrative work — and some believe they should be paid more if the tech increases their efficiency, according to a Doximity report.

Teva Pharmaceuticals is the ‘stalking horse bidder’ to kick off the auction process for BioXcel Therapeutics’ AI-derived assets as the biotech files for Chapter 11 bankruptcy.

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes.

Lisraya carries a boxed warning typical of JAK inhibitors, but otherwise has a broad label that allows use in all adults with the rare autoimmune disease, setting up the drug for blockbuster status in a few years, according to Leerink.

Through its DualityBio deal, Roche’s Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.